Luminex Secures BARDA Funding To Develop And Validate Flu/COVID-19 Combo Respiratory Panel
- Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can run on all ARIES Systems.
- These six and 12-cassette systems are automated molecular diagnostic platforms and produce results in less than two hours.
- Luminex developed the original ARIES SARS-CoV-2 Assay with financial support from BARDA and received an Emergency Use Authorization from FDA for COVID-19 testing in April last year.
- Luminex will submit the targeted multiplex respiratory panel, the ARIES Flu A/B & RSV+SARS-CoV-2 Assay, to the FDA for Emergency Use Authorization as soon as possible.
- Price Action: LMNX stock closed 0.34% lower at $29.56 on Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
